Skip to search formSkip to main contentSkip to account menu

caracemide

Known as: Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI), Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI), N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea 
An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased… 
National Institutes of Health

Related topics

Related topics

2 relations
analogs & derivatives

Broader (1)

hydroxyurea

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Tritiation and characterization of several suicide substrate enzyme inactivators.
2004
2004
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer
SummaryForty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with… 
2004
2004
Release of methyl isocyanate from the antitumor agent caracemide (NSC-253272)
In recent phase 1 clinical trials, caracemide [N-acetyl-N-(methylcarbamoyloxy)-N-methylurea; NSC-253272] has demonstrated a… 
1992
1992
Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma
Caracemide (NacetylN(methylcarbamoyloxy)N-methylurea) is a nonspecific inhibitor of macromolecular synthesis [1]. It has in vitro… 
1990
1990
In vivo and in vitro cholinesterase inhibitor property of the antitumor agent caracemide.
The antitumor agent caracemide [N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea] has been observed to induce signs of cholinergic… 
1988
1988
In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors.
The cytotoxic effect of caracemide and hydroxyurea was compared in human chronic myeloid leukemia cells. Caracemide was found to… 
1987
1987
Phase I trial of caracemide using bolus and infusion schedules.
We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon… 
1987
1987
Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an…
1987
1987
Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion
SummaryA Phase I study of caracemide evaluating a short intravenous infusion repeated every 21 days is presented. Patients were… 
1984
1984
Inhibition of ribonucleotide reductase by caracemide.
Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from rat… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)